330 related articles for article (PubMed ID: 32461262)
1. Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study.
Mansour SE; Kiernan DF; Roth DB; Eichenbaum D; Holekamp NM; Kaba S; Werts E
Br J Ophthalmol; 2021 Mar; 105(3):414-419. PubMed ID: 32461262
[TBL] [Abstract][Full Text] [Related]
2. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study.
Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH
Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472
[TBL] [Abstract][Full Text] [Related]
3. The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema.
Vaz-Pereira S; Castro-de-Sousa JP; Martins D; Prates Canelas J; Reis P; Sampaio A; Urbano H; Kaku P; Nascimento J; Marques-Neves C
Ophthalmic Res; 2020; 63(2):114-121. PubMed ID: 31801148
[TBL] [Abstract][Full Text] [Related]
4. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries.
Chakravarthy U; Taylor SR; Koch FHJ; Castro de Sousa JP; Bailey C;
Br J Ophthalmol; 2019 Aug; 103(8):1072-1077. PubMed ID: 30242062
[TBL] [Abstract][Full Text] [Related]
5. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom.
Bailey C; Chakravarthy U; Lotery A; Menon G; Talks J;
Eye (Lond); 2017 Dec; 31(12):1707-1715. PubMed ID: 28737758
[TBL] [Abstract][Full Text] [Related]
6. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.
Fusi-Rubiano W; Mukherjee C; Lane M; Tsaloumas MD; Glover N; Kidess A; Denniston AK; Palmer HE; Manna A; Morjaria R
BMC Ophthalmol; 2018 Feb; 18(1):62. PubMed ID: 29486754
[TBL] [Abstract][Full Text] [Related]
7. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
[TBL] [Abstract][Full Text] [Related]
8. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience.
El-Ghrably I; Steel DHW; Habib M; Vaideanu-Collins D; Manvikar S; Hillier RJ
Eur J Ophthalmol; 2017 May; 27(3):357-362. PubMed ID: 28165610
[TBL] [Abstract][Full Text] [Related]
9. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
Holden SE; Kapik B; Beiderbeck AB; Currie CJ
Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
[No Abstract] [Full Text] [Related]
10. The 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: Intraocular Pressure-Related Effects over 36 Months.
Roth DB; Eichenbaum D; Malik D; Radcliffe NM; Cutino A; Small KW;
Ophthalmol Retina; 2024 Jan; 8(1):49-54. PubMed ID: 37586482
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy.
Meireles A; Goldsmith C; El-Ghrably I; Erginay A; Habib M; Pessoa B; Coelho J; Patel T; Tadayoni R; Massin P; Atorf J; Augustin AJ
Eye (Lond); 2017 May; 31(5):684-690. PubMed ID: 28085139
[TBL] [Abstract][Full Text] [Related]
12. Discontinuous to continuous therapy for persistent diabetic macular edema leads to reduction in treatment frequency.
Adams OE; Schechet SA; Hariprasad SM
Eur J Ophthalmol; 2021 Mar; 31(2):612-619. PubMed ID: 31964171
[TBL] [Abstract][Full Text] [Related]
13. Reduction in Retinal Thickness Fluctuations After Treatment With Fluocinolone Acetonide Implant for DME: A Post-Hoc Analysis of the USER Study.
Riemann CD; Eaton AM; Cutino A
Ophthalmic Surg Lasers Imaging Retina; 2020 May; 51(5):298-306. PubMed ID: 32511735
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal steroids for macular edema in diabetes.
Rittiphairoj T; Mir TA; Li T; Virgili G
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005656. PubMed ID: 33206392
[TBL] [Abstract][Full Text] [Related]
15. The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema.
Cicinelli MV; Rosenblatt A; Grosso D; Zollet P; Capone L; Rabiolo A; Lattanzio R; Loewenstein A; Bandello F;
Eye (Lond); 2021 Dec; 35(12):3232-3242. PubMed ID: 33479485
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Intraocular Pressure Increases and Management Strategies Following Treatment With Fluocinolone Acetonide Intravitreal Implants in the FAME Trials.
Parrish RK; Campochiaro PA; Pearson PA; Green K; Traverso CE;
Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):426-35. PubMed ID: 27183546
[TBL] [Abstract][Full Text] [Related]
17. The 0.19-mg Fluocinolone Acetonide Intravitreal Implant Reduces Treatment Burden in Diabetic Macular Edema.
Merrill PT; Holekamp N; Roth D; Kasper J; Grigorian R;
Am J Ophthalmol; 2023 Apr; 248():16-23. PubMed ID: 36223849
[TBL] [Abstract][Full Text] [Related]
18. The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN
Panos GD; Arruti N; Patra S
Eur J Ophthalmol; 2021 Mar; 31(2):620-629. PubMed ID: 31906704
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P
Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051
[TBL] [Abstract][Full Text] [Related]
20. The USER Study: A Chart Review of Patients Receiving a 0.2 µg/day Fluocinolone Acetonide Implant for Diabetic Macular Edema.
Eaton A; Koh SS; Jimenez J; Riemann CD
Ophthalmol Ther; 2019 Mar; 8(1):51-62. PubMed ID: 30560505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
